DK3359185T3 - ANTITUMORAL COMPOSITION - Google Patents
ANTITUMORAL COMPOSITION Download PDFInfo
- Publication number
- DK3359185T3 DK3359185T3 DK16794685.4T DK16794685T DK3359185T3 DK 3359185 T3 DK3359185 T3 DK 3359185T3 DK 16794685 T DK16794685 T DK 16794685T DK 3359185 T3 DK3359185 T3 DK 3359185T3
- Authority
- DK
- Denmark
- Prior art keywords
- antitumoral composition
- antitumoral
- composition
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1559589A FR3042121A1 (en) | 2015-10-08 | 2015-10-08 | ANTI-TUMOR COMPOSITION |
| FR1659450A FR3042122B1 (en) | 2015-10-08 | 2016-09-30 | ANTI-TUMOR COMPOSITION |
| PCT/FR2016/052598 WO2017060650A1 (en) | 2015-10-08 | 2016-10-07 | Anti-tumoral composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3359185T3 true DK3359185T3 (en) | 2022-07-04 |
Family
ID=55178130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16794685.4T DK3359185T3 (en) | 2015-10-08 | 2016-10-07 | ANTITUMORAL COMPOSITION |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180296653A1 (en) |
| EP (1) | EP3359185B1 (en) |
| JP (1) | JP7211815B2 (en) |
| KR (1) | KR20180059547A (en) |
| CN (1) | CN108348587A (en) |
| CA (1) | CA2999948C (en) |
| DK (1) | DK3359185T3 (en) |
| ES (1) | ES2919134T3 (en) |
| FR (2) | FR3042121A1 (en) |
| HK (1) | HK1253315A1 (en) |
| IL (1) | IL258430B (en) |
| LT (1) | LT3359185T (en) |
| RU (1) | RU2728748C2 (en) |
| WO (1) | WO2017060650A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| CN116676324B (en) * | 2023-07-28 | 2023-10-27 | 四川大学华西医院 | System and method for constructing and releasing anti-tumor effector protein based on Kil protein |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751879B1 (en) * | 1996-07-30 | 1998-10-30 | Transgene Sa | PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND PAPILLOMAVIRUS INFECTIONS |
| US6869793B2 (en) | 1996-09-24 | 2005-03-22 | Bavarian Nordic Research Institute | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| ID24941A (en) | 1997-09-23 | 2000-08-31 | Bavarin Nordic Res Inst A S Cs | ANTIGENAL VIRUS Dengue and treatment of dengue fever |
| US6682743B2 (en) | 2000-03-14 | 2004-01-27 | Bavarian Nordic A/S | Altered strain of the modified vaccinia virus ankara (MVA) |
| EE05680B1 (en) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Modified vaccine virus, its preparation and use, pharmaceutical composition containing it and vaccine |
| UA82466C2 (en) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Method for intensification of chordopoxvirus amplification |
| EP1456230A2 (en) | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| IL161590A0 (en) | 2001-12-10 | 2004-09-27 | Bavarian Nordic As | Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| SI1407006T1 (en) | 2001-12-20 | 2006-04-30 | Bavarian Nordic As | Method for the recovery and purification of poxviruses from infected cells |
| AU2003239805B2 (en) | 2002-04-19 | 2009-09-10 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| JP4895505B2 (en) | 2002-05-16 | 2012-03-14 | バヴァリアン・ノルディック・アクティーゼルスカブ | Intergenic region as an insertion site in the mutated vaccinia virus Ankara (MVA) genome |
| BR0310020A (en) | 2002-05-16 | 2005-02-15 | Bavarian Nordic As | Expression of genes in modified vaccinia virus ankara by use of vaccinia ati promoter |
| CN1325512C (en) | 2002-05-16 | 2007-07-11 | 巴法里安诺迪克有限公司 | Fusion protein of HIV regulatory/accessory proteins |
| GB0221574D0 (en) * | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| CA2507469C (en) | 2002-11-25 | 2015-04-28 | Den Kgl. Veterinaer-Og Landbohojskole | Porcine polymorphisms and methods for detecting them |
| ES2288634T3 (en) | 2002-11-25 | 2008-01-16 | Bavarian Nordic A/S | RECOMBINANT POXVIRUS THAT UNDERSTANDS AT LEAST TWO ATI PROMOTERS OF THE VIRUELA DE LAS VACAS. |
| CN1802174A (en) * | 2003-04-15 | 2006-07-12 | 圣诺菲·帕斯图尔有限公司 | Tumor antigen BFA5 for prevention and / or treatment of cancer |
| DE602004009743T2 (en) | 2003-11-24 | 2008-08-28 | Bavarian Nordic A/S | Promoters for expression in modified vaccinia virus Ankara |
| AU2006218115B2 (en) | 2005-02-23 | 2012-08-02 | Bavarian Nordic A/S | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| US20100011451A1 (en) | 2006-09-08 | 2010-01-14 | Paul Chaplin | Phenotypic and genotypic differences of mva strains |
| AU2007307080B2 (en) | 2006-10-06 | 2014-01-09 | Bavarian Nordic A/S | Methods for treating cancer with MVA |
| NZ578959A (en) | 2007-04-27 | 2012-12-21 | Bavarian Nordic As | Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf) |
| US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| WO2008138533A1 (en) | 2007-05-14 | 2008-11-20 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| NZ601827A (en) | 2007-10-18 | 2014-01-31 | Bavarian Nordic Inc | Use of mva to treat prostate cancer |
| US20110268744A1 (en) * | 2008-05-26 | 2011-11-03 | Ian Garthwaite | Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor |
| EP2303322A1 (en) | 2008-06-20 | 2011-04-06 | Bavarian Nordic A/S | Recombinant modified vaccinia virus measles vaccine |
| CA2742247C (en) | 2008-11-21 | 2017-07-04 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
| AU2009319336B2 (en) | 2008-11-27 | 2015-03-26 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| GB0901593D0 (en) | 2009-01-30 | 2009-03-11 | Touchlight Genetics Ltd | Production of closed linear DNA |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| AU2010305030A1 (en) | 2009-10-08 | 2012-05-10 | Bavarian Nordic A/S | Generation of a broad T-cell response in humans against HIV |
| NZ600629A (en) | 2010-01-28 | 2014-12-24 | Bavarian Nordic As | Vaccinia virus mutants containing the major genomic deletions of mva |
| CA2802430C (en) | 2010-07-20 | 2021-07-20 | Bavarian Nordic A/S | Method for harvesting poxvirus |
| GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| JP5933565B2 (en) | 2010-10-15 | 2016-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | Recombinant modified vaccinia virus Ankara influenza vaccine |
| AU2011325459B2 (en) | 2010-11-05 | 2016-11-10 | Bavarian Nordic A/S | Modulation of immune responses by the poxviral K4 protein |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| EP3656396A1 (en) | 2012-08-01 | 2020-05-27 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
| US10973892B2 (en) | 2012-09-04 | 2021-04-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| CA2888367A1 (en) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
| PT2912183T (en) | 2012-10-28 | 2020-06-05 | Bavarian Nordic As | Pr13.5 promoter for robust t-cell and antibody responses |
| US9402888B2 (en) * | 2013-03-14 | 2016-08-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
| US20160271239A1 (en) * | 2013-11-05 | 2016-09-22 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor |
| KR20230076867A (en) * | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | Combination therapy with neoantigen vaccine |
| US10548930B2 (en) * | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
-
2015
- 2015-10-08 FR FR1559589A patent/FR3042121A1/en active Pending
-
2016
- 2016-09-30 FR FR1659450A patent/FR3042122B1/en active Active
- 2016-10-07 JP JP2018515877A patent/JP7211815B2/en active Active
- 2016-10-07 RU RU2018115534A patent/RU2728748C2/en active
- 2016-10-07 LT LTEPPCT/FR2016/052598T patent/LT3359185T/en unknown
- 2016-10-07 US US15/766,510 patent/US20180296653A1/en not_active Abandoned
- 2016-10-07 DK DK16794685.4T patent/DK3359185T3/en active
- 2016-10-07 CN CN201680058083.7A patent/CN108348587A/en active Pending
- 2016-10-07 EP EP16794685.4A patent/EP3359185B1/en active Active
- 2016-10-07 CA CA2999948A patent/CA2999948C/en active Active
- 2016-10-07 WO PCT/FR2016/052598 patent/WO2017060650A1/en active Application Filing
- 2016-10-07 KR KR1020187012825A patent/KR20180059547A/en not_active Application Discontinuation
- 2016-10-07 ES ES16794685T patent/ES2919134T3/en active Active
-
2018
- 2018-03-28 IL IL258430A patent/IL258430B/en unknown
- 2018-10-02 HK HK18112608.9A patent/HK1253315A1/en unknown
-
2021
- 2021-01-19 US US17/152,031 patent/US20210138053A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018115534A3 (en) | 2020-02-26 |
| IL258430A (en) | 2018-06-28 |
| RU2018115534A (en) | 2019-11-08 |
| RU2728748C2 (en) | 2020-07-31 |
| KR20180059547A (en) | 2018-06-04 |
| WO2017060650A1 (en) | 2017-04-13 |
| CA2999948A1 (en) | 2017-04-13 |
| JP7211815B2 (en) | 2023-01-24 |
| FR3042122B1 (en) | 2020-01-17 |
| CA2999948C (en) | 2024-04-23 |
| JP2018531238A (en) | 2018-10-25 |
| EP3359185B1 (en) | 2022-04-06 |
| IL258430B (en) | 2022-03-01 |
| US20180296653A1 (en) | 2018-10-18 |
| FR3042121A1 (en) | 2017-04-14 |
| CN108348587A (en) | 2018-07-31 |
| HK1253315A1 (en) | 2019-06-14 |
| US20210138053A1 (en) | 2021-05-13 |
| ES2919134T3 (en) | 2022-07-22 |
| LT3359185T (en) | 2022-06-27 |
| EP3359185A1 (en) | 2018-08-15 |
| FR3042122A1 (en) | 2017-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3283625T3 (en) | NUCLEASE-MEDIED GENOMEDITING | |
| DK3361870T3 (en) | FUNCTIONAL COMPOSITIONS | |
| DK3305788T3 (en) | JANUS-KINASE-HIMMER | |
| DK3277719T3 (en) | POLYPEPTIDER | |
| DK3215173T3 (en) | GLYCOPEPTIME COMPOSITIONS | |
| DK3040326T3 (en) | HALOOLEFIN-BASED COMPOSITION | |
| DK3416996T3 (en) | HARDLY COMPOSITION | |
| DK3334726T3 (en) | PLINABULIN COMPOSITIONS | |
| FR3024363B1 (en) | THERMOGELIFIABLE COMPOSITION | |
| DK3250182T3 (en) | DISPERGIBLE COMPOSITIONS | |
| DK3270930T3 (en) | PRE-CLAMPSY | |
| DK3528902T3 (en) | RINGEGEL COMPOSITION | |
| DK3292136T3 (en) | PENICILLIN-G-ACYLASER | |
| CL2017000639A1 (en) | Composition | |
| DK3331498T3 (en) | NATIONAL COMPOSITION | |
| DK3316857T3 (en) | MULTIFASIC COMPOSITIONS | |
| DK3274482T3 (en) | STENBORSKNOP | |
| DE112015006486A5 (en) | Inkubationsrinne | |
| DK3393254T3 (en) | COMPOSITION | |
| DK3200827T3 (en) | COMPOSITIONS | |
| DK3416502T3 (en) | GLYCEMIC-REDUCING COMPOSITION | |
| DE112016005599A5 (en) | grillers | |
| DK3337322T3 (en) | FUNCTIONAL COMPOSITIONS | |
| BR112017016240A2 (en) | composition | |
| DK3288536T3 (en) | COMPOSITIONS COMPREHENSIVE ANAKINRA |